Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Calza

Showing results (111-120 of 188) with videos related to

Pageof 19
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2020
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 InfectionLeonardo Calza, Isabella Bon, Marco Borderi, et al.
HIV Research & Clinical Practice|February 18, 2020
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapyLeonardo Calza, Marco Borderi, Bianca Granozzi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapyGabriella Verucchi, Leonardo Calza, Carlo Biagetti, et al.
AIDS (London, England)|December 7, 2021
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravirLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
AIDS (London, England)|January 7, 2017
Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patientsLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapyLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Infectious Diseases (London, England)|September 21, 2020
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndromeLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
AIDS Research and Human Retroviruses|October 31, 2020
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or RaltegravirLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Journal of Medical Virology|April 17, 2020
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern ItalyLeonardo Calza, Martina Tamburello, Marco Borderi, et al.
AIDS (London, England)|October 4, 2008
Abacavir-induced febrile agranulocytosis and anaemiaLeonardo Calza, Nicola Dentale, Benedetta Piergentili, et al.
Pageof 19

Showing results (111-120 of 188) with videos related to

Sort By:
Pageof 19
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2020
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 InfectionLeonardo Calza, Isabella Bon, Marco Borderi, et al.
HIV Research & Clinical Practice|February 18, 2020
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapyLeonardo Calza, Marco Borderi, Bianca Granozzi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 13, 2004
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapyGabriella Verucchi, Leonardo Calza, Carlo Biagetti, et al.
AIDS (London, England)|December 7, 2021
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravirLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
AIDS (London, England)|January 7, 2017
Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patientsLeonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2020
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapyLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Infectious Diseases (London, England)|September 21, 2020
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndromeLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
AIDS Research and Human Retroviruses|October 31, 2020
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or RaltegravirLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Journal of Medical Virology|April 17, 2020
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern ItalyLeonardo Calza, Martina Tamburello, Marco Borderi, et al.
AIDS (London, England)|October 4, 2008
Abacavir-induced febrile agranulocytosis and anaemiaLeonardo Calza, Nicola Dentale, Benedetta Piergentili, et al.
Pageof 19